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REV I EWB IOMATER IALSBiomaterial-Associated Infection: Locating the Finish
Line in the Race for the Surface
Henk J. Busscher,1 Henny C. van der Mei,1* Guruprakash Subbiahdoss,1 Paul C. Jutte,2
Jan J. A. M. van den Dungen,3 Sebastian A. J. Zaat,4 Marcus J. Schultz,5 David W. Grainger6,7Biomaterial-associated infections occur on both permanent implants and temporary devices for restoration or
support of human functions. Despite increasing use of biomaterials in an aging society, comparatively few
biomaterials have been designed that effectively reduce the incidence of biomaterial-associated infections. This
review provides design guidelines for infection-reducing strategies based on the concept that the fate of bio-





























 BACTERIA VERSUS HOST TISSUE
Currently, we face unusually long life expectancies, while at the same
time, people expect a high quality of life to accompany aging. Yet, no
matter how well human life-styles are adapted to protect against injury
and to age in healthy ways, the body eventually reaches a state exceeding
its capacity for effective natural repair. In some cases, severe trauma dam-
ages human tissues beyond repair. Also, tumor resections—a common
procedure as we age—can create irreparable damage or structural defects
that do not heal. More naturally, increasing wear within musculoskeletal
joints becomes less amenable to repair by innate host processes.
Today, however, irreparable damage to the human body does not
necessarily imply functional loss or reduced quality of life. Frequently,
functional restoration is achieved surgically using permanently im-
planted biomaterials and devices like total joint arthroplasties and
the artificial heart, respectively, or using instruments and temporary
devices for transient intervention to help promote tissue regeneration,
functional restoration, and healing, like a pulmonary assist device and
urinary or intravenous catheters. Implant and device composition and
application may differ widely—from the artificial heart to prosthetic joints
to vascular prostheses to dental implants to contact lenses—but all at-
tract microorganisms, thus representing niches for infection in vivo
(Table 1). Continued microbial presence interferes with the intended
function of an implant or device and adds risk to human use. Indeed,
infections surrounding foreign body materials have been recognized
since the 14th century when the French surgeon Guy de Chauliac,
Pope Clement VI’s personal physician, advised removal of all foreign
bodies from infected wound sites in his surgical handbook, Chirurgia
Magna (9). Implant infections have a substantial and largely unchanged
clinical incidence, associated mortality and morbidity, and significant
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www.ScienceTrIncreasing use of biomaterial implants and devices accompanies
our growing life expectancies and exacerbates these problems. In par-
ticular, permanent, totally internal biomaterial implants and devices
face two challenges with respect to their extended use in vivo: biomaterial-
associated infection and lack of native tissue integration (10). Anthony
Gristina (10) coined the phrase the “race for the surface,” suggesting
that tissue cell integration and bacterial adhesion compete for real es-
tate on the implant’s surface.One hopes that the race is won by the host
tissue, “defending” the implant surface from invading pathogens by im-
plant integration and vigorous immune competence.
Nevertheless, bacteria can also “win” with dire patient consequences.
Because implant microbial colonization is the prelude to biomaterial-
associated infection (11, 12), biomaterial surface properties have long
been the focus for understanding microbial adhesion and infection
mechanisms as well as for the design of preventive measures. Nonetheless,
progress in improving biomaterial surfaces and the design of coatings
to prevent microbial colonization has been limited. Central to this lack
of progress is the failure of design technologies for both coatings and
new biomaterials that reduce ubiquitous bacterial adhesion occurring
on every material surface, as well as strategies that effectively block mi-
crobial phenotypic changes upon adhesion, including the production
of extracellular polymeric substances (13) in which bacteria embed
and protect themselves in their biofilm mode of growth. Organisms in
a biofilm mode of growth may be metabolically less active, facilitating
resistance to antimicrobial agents (14). Such metabolically reduced or
senescent phenotypes allow organisms to survive in long-lasting dor-
mant states despite antibiotic treatment. This highly protective biofilm
phenotype enables microorganisms colonizing a biomaterial surface to
evade antibiotics and host immune responses for up to several years
before awakening in more virulent modes (15). The immune responses
that should clear bacteria from the surrounding tissue are severely
compromised by the trauma associated with surgical implantation as
well as by the resulting presence of a foreign body in the tissue, thus
frustrating phagocytic activity and deranging the host immune response.
This ultimately allows bacterial survival both on and around the im-
plant or device. More than 3 centuries ago, Antonie van Leeuwenhoek
discovered that vinegar, an antimicrobial used at the time to kill oral
biofilm, did not penetrate in a biofilm and killed only bacteria at the
outside of the biofilm, therewith referring to the protective, biofilm
mode of growth of microorganisms on his tooth surfaces. We now find






























 Although lack of progress over 3 centuries to design biomaterial
surfaces that prevent biofilm formation is frustrating scientifically, our
inability to prevent biomaterial-associated infections is increasingly con-
sidered socially and medically unacceptable. Opinions differ on whether
current infection incidences in various applications (Table 1) are high or
low with respect to the benefits of a biomaterial implant or device intended
to improve the patient’s quality of life. Higher risks can be accepted, for
instance, in case of potentially fatal disturbances of cardiac rhythm using
pacing devices, more so than for implant surgeries solely aiming at cos-
metic effects. However, there is increasing social intolerance toward
implant-associated infection: Resulting infections are frequently accom-
panied by patient morbidity and discomfort and can lead to surgical
replacement of the implant after lengthy, unsuccessful attempts to mit-
igate infections with antibiotic treatments. This tedious clinical routine
incurs additional health care costs and patient morbidities. Revision
surgery to replace a total hip arthroplasty triples the cost of the primary
implant procedure and amounts to an average of $75,000 (16, 17). Since
2008, the U.S. Centers for Medicare & Medicaid Services have stopped
reimbursing hospitals for eight conditions with evidence-based preven-
tion guidelines, including coronary artery bypass graft and catheter-
associated infections. Hospitals in various countries worldwide are held
directly accountable for biomaterial-associated infections (18).www.ScienceTrThis historical inability to produce clinically effective, infection-
resistant biomaterial implants and devices can be attributed in part to
the complexity of the problem. The various scientific disciplines address-
ing the issues may not approach the problem in a sufficiently interactive
manner. Therefore, this Review aims to describe major hurdles that
impede clinical progress after initial discoveries by van Leeuwenhoek
more than 300 years ago and by Gristina more than 25 years ago, who
provided a more modern, unique, comprehensive, and multidisciplinary
insight into biomaterial-associated infections.PROTECTING THE PRIMARY IMPLANT PATIENT
A technically successful operation is no guarantee against biomaterial-
associated infections. In the absence of skin-penetrating trauma, it is
likely that the organisms causing implant infection have either entered
the wound site or attached to the implant during surgery (termed
perioperative contamination) or during hospitalization, before wound
closure (termed early postoperative contamination). No surgical suite
is truly sterile (19), and sources of contaminating pathogens are present
in most operating theaters (20); therefore, both routes of microbial
contamination are common in all surgeries and postoperative hos-
pitalizations but pose greater risks in biomaterial implant surgeries
because organisms that adhere to implant surfaces and revert to their pro-
tective biofilm phenotype and/or enter senescent states can survive—
often unnoticed by the host immune system. Under these conditions,
pathogens can cause clinically significant infections, even many years
after surgery (21).
Sterile implant surgery may therefore be considered a myth, and
estimates are that in a standard operating theater during a surgical
procedure of 1 hour, the total number of bacteria-laden particles fall-
ing into a wound amounts to about 270 bacteria/cm2 (22). More recently,
through the use of modern, better-ventilated operation theaters (20 changes
of air per hour) and impermeable clothing, perioperative bacterial con-
tamination may be less (23). Nevertheless, many surgical procedures
in which implants are placed in the body last longer than 1 hour, suf-
ficiently long for considerable bacterial contamination to occur. Contam-
ination is generally higher during periods of personnel movement and
surgical activity, and when more people are present in the operation the-
ater. Hence, discipline among personnel in the operation theater is also
involved in the prevention of perioperative contamination (24). Apart
from these nonpatient sources of perioperative contamination, com-
mensal bacteria residing in the deeper layers of patients’ skin cannot
be killed by regular disinfection and may be “released” to the wound
site upon scalpel insertion and incision (25–27).
Figure 1 exemplifies adverse events possibly occurring after a tech-
nically successful implant surgery. Other than infection from peri- or
early postoperative contamination that can be noted almost immedi-
ately (if not falsely taken for an occasional influenza), clinical signs of
infection may not appear until many years later. A biomaterial implant
or device remains at risk of infection by hematogenous spread of
bacteria disseminated from infections elsewhere in the body or enter-
ing the bloodstream after routine dental treatments or minor skin-
penetrating trauma. In such circumstances, effective protection is only
offered by integration of the biomaterial into host tissues and estab-
lishment of a normal host immune response at the implant site.
Gristina (10) was acutely aware that biomaterial surfaces needed to
be modified to improve compatibility and tissue integration to resistTable 1. Incidence of biomaterial-associated infection for different im-
plants and devices. Incidence data are given over the entire implant or device
lifetime, unless stated otherwise.Tissue implant
siteImplant or
deviceInfection incidence
over lifetime (%)ReferencesUrinary tract Catheter 33 (per week) (1, 2)Percutaneous Central venous
catheter2–10 (1)Temporary pacemaker 4 (3)Short indwelling
catheter0–3 (2)Peritoneal dialysis
catheter3–5 (2)Fixation pin or screw 5–10 (1)Sutures 1–5 (4)Voice prosthesis 25 (per month) (5)Dental implant 5–10 (1)Subcutaneous Cardiac pacemaker 1–7 (1)Penile prosthesis 2–5 (1)Soft tissue Mammary prosthesis 1–7 (2)Abdominal wall patch 1–16 (6)Intraocular lens 0.1 (2)Eye Contact lens 0.1–0.5 (7)Circulatory














rgmicrobial colonization. Notably, surface modification remains the most
frequently adopted route to reduce the incidence of biomaterial-associated
infection (28–30). Unfortunately, performance demands and expecta-
tions imposed on many coatings by clinicians and patients to address
infection risks are ill-defined. These demands and expectations ne-
glect the crucial distinction between a host tissue environment before
primary implantation and the environment surrounding an infected im-
plant or device that must be replaced (revision surgery). Primary im-
plant surgery involves low numbers of contaminating bacteria, wherein
tissue surrounding the implant site is initially uncompromised by bacte-
ria. This is distinct from a failing, infected implant requiring replace-
ment, where the tissue surrounding the implant can also be infected,
compromised, inflamed, and possibly necrotic. In many cases, systemic
antibiotics, local antibiotic release from implant coatings (31), or device
fixation materials, such as antibiotic-loaded bone cements (32), suffice to
mitigate microbial contamination developed during primary hospitaliza-
tion. However, revision surgery often requires retraumatizing the already-
infected implant site, tissue debridement with the risk of disseminating
resident bacteria, further loss of tissue, and creation of poorly perfused
tissue defects and voids.
Costs and health consequences of implant-associated infections are sub-
stantial, and research efforts that more effectively address implant fail-
ure resulting from both peri- and early postoperative contamination
during hospitalization are needed. This encompasses biomaterial surface
modifications that ensure patients that all hospital-acquired organisms
endangering the implant or device are killed and cleared rapidly upon
or immediately after implantation. Societal pressure to achieve such designwww.ScienceTrimprovements is increasing because we all desire a “warranty,” or guar-
antee, that the service or implant will have lasting, positive effects
without a risk of infection. Antimicrobial implants and devices should
not impair the local host immune competence. Depending on the
application, implants are also expected to stimulate tissue integration
while simultaneously preventing microbial adhesion, killing all orga-
nisms both active and dormant, present on and around the implant or
device. These performance requirements put a restraint on the time
period that these coatings should remain reliable and effective. In gen-
eral, coatings that negate the effects of microbial contamination acquired
during hospitalization or surgery should complete this task within 2 to
3 weeks after implantation. Longer implant protection is of course desir-
able to prevent infection of an implant site through the hematogenous
route, but this long-term performance is currently technically not pos-
sible by lack of appropriate biomaterials and coatings.PROTECTING THE REVISION IMPLANT PATIENT
Revision surgeries after implant infection are cumbersome because
they suffer from higher infection incidences than primary implants. For
orthopedic joint prostheses, the growing number of national and in-
ternational registries, such as the Swedish Hip Arthroplasty Registry
(33), comprising thousands of patients followed over many decades,
provides clear, statistically supported evidence that secondary prostheses
placed after infections are at greater risk for infection than primary
















 are scarce, because only a small fraction
of all implant patients undergo revision
surgery due to infection. Penile prostheses,
for instance, have an infection incidence
of 2 to 5%, but in revision patients with im-
plant infections, this increases to 10% (34).
Secondary implants and devices placed
after infections require different approaches
to mitigation because bacteria residing in
peri-implant tissue can proliferate if not
adequately eliminated before revision sur-
gery, causing resuscitation of infection. In
one study, routine hospital cultures of tis-
sue sampled from regions surrounding
failed joint prostheses exhibited bacterial
growth in 9 of 22 cases, increasing to 14
cases after extended culturing (35). In live
bone tissue excised from a patient with
recurrent, long-term osteomyelitis, bacte-
ria were observed inside osteoblasts and
osteoclasts (36). Moreover, the importance
of peri-implant tissue reservoirs for reseed-
ing biomaterial-associated infection has
been extensively shown in murine im-
plant models. Staphylococcus epidermidis
colonized the peri-implant tissue surround-
ing silicone rubber subcutaneous implants
in mice where bacteria survived in high
numbers, even within resident macro-
phages (21). Bacteria in the implant-
















Fig. 1. Patient risk factors for developing a biomaterial-associated infection. Revision surgery patients are
at greater risk than primary surgery implant patients, whereas the risk of an implant or device becoming
infected hematogenously decreases with time after implant placement due to more extensive host tissue






























 Similarly, pericatheter tissue samples of intensive care unit patients
who had died from noninfectious causes were positive for bacteria
both in culture and immunohistology, even in biopsies from tissues
not bordering the catheter (38). This suggests that pericatheter tissues
also provide a niche for infecting bacteria.
Clinically, antibiotics are chosen to be active against bacteria in
biofilms, but the additional need to kill bacteria in niches, such as peri-
implant tissue or intracellular locations, is not always considered, or
even possible. Antibiotics such as vancomycin and gentamicin have
low—if any—activity against intracellular bacteria. Other antibiotics,
such as rifampicin or fluoroquinolones, target intracellular bacteria,
but pathogen resistance to these antibiotics develops rapidly, only re-
quiring single point mutations. In the case of rifampicin-vancomycin
combinations often used to treat biomaterial-associated infection, only
rifampicin reaches intracellular bacteria; so, these bacteria are actually
subjected to rifampicin monotherapy, yielding a high risk of resistance
development. Combinations of rifampicin with other antibiotics may
in part derive their efficacy for optimized clearance of intracellularly
resident bacteria from results in animal infection models (39–41) and
in patients (42, 43).
In clinical orthopedics, elimination of bacteria from infected peri-
implant tissue in revision surgery is primarily achieved by two-stage
revision surgery in which the infected prosthesis is removed, the host
bed is rigorously cleaned, antibiotics are systemically and locally de-
livered for a prolonged period of time, and a new prosthesis is placed
only when the infection has fully cleared and surrounding tissue is no
longer compromised. Not all applications, however, allow a two-stage
revision, and secondary implants sometimes have to be placed into
contaminated tissue in single-stage surgical exchanges, like with an in-
fected vascular graft. Aggressive and long-term antibiotic therapy is
then essential to protect the revision implant or device in its compro-
mised tissue environment to prevent recontamination over time by per-
sister organisms that have survived initial antibiotic treatment. Initial
antibiotic treatment not only comprises systemic antibiotics but may
also include biomaterial coatings, such as surgical meshes and tibial
nails with gentamicin incorporated in a biodegradable matrix or
antibiotic-releasing bone cements for fixation of joint prostheses (3).
Usually, however, the clearance of organisms from infected surround-
ing tissues requires high local concentrations of antibiotics at these
tissue sites, extending the time periods over which current coatings
release effective concentrations of antibiotics (usually 3 to 4 days, in-
cluding a high initial burst release within 1 to 2 days).DEVICE COATING AND DESIGN STRATEGIES
All biomaterial implants and devices can be adversely affected by mi-
crobial contamination and clinical infection. However, device coating
strategies are often evaluated and applied without considering impor-
tant details unique or specific to each application. This is flawed for
many reasons. First, temporary implants, such as feeding tubes, uri-
nary or vascular catheters, and contact lenses, do not require tissue in-
tegration. Therefore, nonadhesive (44, 45), antibiotic-releasing (46),
silver-impregnated (47), or coatings that kill bacteria immediately upon
their adhesion to the coating (48) can prevent implant infection in
these contexts. Regardless, infections arising from temporarily im-
planted medical devices should not be considered less severe: Even
infection caused by devices that can be easily removed can result inwww.ScienceTra life-threatening situation where the physician has to balance the risks
of infection versus the consequences of removing a potentially life-
saving device.
Permanent, totally internal implants and devices designed to selec-
tively favor host tissue integration over bacterial adhesion and biofilm
growth are elusive: Biomaterial surfaces facilitating host cell adhesion,
spreading, and growth are also adhesive to microorganisms because
microorganisms use many of the same adhesive mechanisms as host
tissue cells. An important example is the extracellular matrix (ECM)
protein fibronectin (Fn) (49), a host protein that adsorbs to implants
and devices and is characterized by an integrin receptor–binding motif,
which is also recognized by Staphylococci having Fn-binding proteins
(50). Alternatively, surfaces and coatings designed to prevent bacterial
colonization do not effectively integrate with host cells and tissues.
Functional duplicity between friend and foe has prompted increas-
ing awareness of the futility of using monofunctional surfaces to both
repel and kill bacteria while at the same time promoting tissue cell
adhesion.
Surfaces with multiple functionalities (Fig. 2) that reliably select host
cells over microbes must be created (51). Dual-function coatings use
unique surface chemistries and topological patterns comprising both
adhesive and nonadhesive sites in densities and configurations that se-
lectively encourage tissue cell attachment yet impede adhesion of the
much smaller microorganisms like bacteria (28, 52–54). The number
of functionalities added to a coating can be increased further by includ-
ing moieties that kill bacteria upon their initial adhesion to a surface
(55) or, in realization that biocompatible means more than anti-infection,
moieties that demonstrate, for example, both antimicrobial and anti-
thrombotic properties (56). Such multifunctional coatings give host
cells a leg up in winning the race for the surface, as opposed to often-
reported monofunctional surface chemistries and morphologies that
either discourage microbial adhesion and biofilm growth or promote
host tissue integration but cannot achieve both simultaneously. The
realization that monofunctional coatings will not offer sufficient relief
to the problem of implant and device infection is recent, and therefore,
multifunctional coatings are still in their infancy. Moreover, appropriate
methods for in vitro evaluation of multifunctional coatings are only
slowly emerging.EVALUATING ANTI-INFECTION POTENTIAL IN VITRO
Few in vitro studies reliably culture both bacteria and tissue cells under
conditions relevant to in vivo infection niches. Microbial strains and
tissue-derived cell lines used should be matched to the implant site’s
phenotypes. Urinary catheters, for instance, are predominantly colonized
by Escherichia coli (57). Voice prostheses harvest a mixture of skin
Staphylococci, oral Streptococci, and yeast (58). Pseudomonas aeruginosa
is the primary causative species in contact lens–induced microbial keratitis
(59). Joint prostheses and metal fixation implants usually fail owing to
staphylococcal infections (60). The appropriate bacterial strains should
be used in vitro when evaluating coatings for a specific application in
vivo. In vitro evaluation methods are furthermore distinguished by the
absence or presence of fluid flow, with fluid volumes varying with respect
to biomaterial surface areas and microbial challenge doses applied.
Often, these parameters are unknown for the surrounding of an
implant or device in the body, such as around the stem of a total hip






























 coatings that release antimicrobials, and the design of the assay has a
direct impact on the outcome of any evaluation. Under flow, for example,
biofilms grow on antibiotic-releasing bone cements used for orthopedic
prosthetic fixation, but in small, convection-free fluid volumes, bacteria
are effectively killed, inhibiting biofilm formation (61). Another point of-
ten neglected in the design of in vitro studies is that in vivo bio-www.ScienceTranslationalMedicine.org 26 Sematerials are rapidly covered with layers
of adsorbed proteins from plasma, saliva,
tear fluid, or other bodily fluids, depend-
ing on the implant site. Adsorbed protein
films likely interfere with coating func-
tionalities, which is why in vitro testing
should include the effects of protein ad-
sorption to a biomaterial or coating to
yield relevant results for translation into
people.
Different microbial species—and even
strains within one species—can exhibit
widely differing virulence and patterns
of adhesion and growth on different bio-
material surfaces (62). Culture media for
many in vitro microbiological assays have
no physiological relevance and may yield
different microbial properties than those
observed from organisms grown, for in-
stance, in serum or saliva. Within species,
strain virulence and antibiotic suscepti-
bility vary widely with source and strains
used in in vitro assays; therefore, bacte-
rial strains for in vitro testing must be
carefully selected to prevent a bias toward
favorable results, for example, by using
nonvirulent or highly antibiotic-susceptible
strains.
The shift in philosophy and strategy
toward the design of multifunctional
biomaterials and coatings and their down-
stream translation into clinical applica-
tion necessitates the development of new
in vitro and in vivo approaches to evaluate
them. Many different in vitro methods as-
sess either microbial adhesion and growth
or cell adhesion, spreading, and growth
on biomaterial surfaces. Flow perfusion
devices are often used to this end, either
macroscopic in size (63) or miniaturized
(64–66). Microfluidic devices allow high-
er throughput and use smaller volumes
and lower numbers of organisms, includ-
ing clinical samples, without culturing, but
offer less versatility with respect to the
material to be investigated. Development
of improved in vitro coculture models re-
quires a suitable culture medium in which
both mammalian cells and microorgan-
isms grow naturally and in balance with
one another (67). In a coculture model
using modified media, it was observedthat adhering Staphylococcus aureus and P. aeruginosa caused rapid
death of adhering human U2OS osteoblasts within 24 hours, whereas
U2OS cells survive for at least 48 hours in cocultures with adhering
S. epidermidis (68). Because clinical infections arising from S. aureus
and P. aeruginosa usually progress much more aggressively than







• Contact lenses and lens cases
• Catheters
• Voice prostheses
• Dental implants (subgingival component)
Unsuitable for any implant application
in absence of other antimicrobial 
functionalities
Useful added functionality for all 
applications requiring nonadhesive 
surfaces
Highly suitable in revision surgery
after biomaterial-associated infection 
to clear infection from surrounding 
tissues and local antibiotic prophylaxis 
in primary surgery
Ideal for applications requiring tissue
integration:
• Vascular grafts
• Bone anchoring in dental implants and
   joint prostheses
• Scaffolds in tissue engineering
Fig. 2. Function requirements to biomaterials and coatings in different clinical applications. A schematic
presentation of different antimicrobial functionalities that can be added to the surface of a biomaterial



















rgsignificance as a validation of the coculture model and the modified
medium used.
Coculture models can also be applied to mimic perioperative or late
hematogenous spreading of infectious bacteria, depending on whether
bacteria are adhering to a surface before or after mammalian cell seed-
ing (67, 69). Evaluations in coculture models have shown that when
cells are allowed to first reach a critical cell surface coverage before bac-
terial challenges, the chances for bacteria to colonize a surface are
strongly reduced (69). This supports the notion that tissue integration
is the best protection for a permanent, totally internal implant or de-
vice. This is also consistent with a clinical study on infection of total
hip arthroplasties that demonstrated that infection opportunities
from hematogenous sources are greatest in the first 6 postoperative
weeks, during which time tissue integration is still incomplete and
ongoing (70).
In vitro coculture studies are needed to provide different conclu-
sions from the long-used and poorly predictive monoculture studies
with either bacteria or tissue cells. On a bifunctional surface having
specific tissue-reactive sites, coculture studies have demonstrated that
favorable effects of such sites on mammalian cell interaction seen in
monoculture studies may disappear in the presence of Staphylococci
owing to the preferential adsorption of bacterial extracellular polymeric
substances on the tissue-reactive groups, thereby blocking host tissue
cell accessibility (71). Microfluidic devices have been used to investi-
gate simultaneous interactions of osteoblast-like cells and S. epidermidis
on a titanium surface (64) and were also extended to assay microbial
biofilm formation on three-dimensional tissue cell growth (65) and
collagen scaffolds (66), as in tissue-engineering scenarios. Unfortunately,
despite their more predictive capabilities than monoculture counter-
parts, coculture studies are tedious and time-consuming, which does










 VIRTUES OF IN VITRO VERSUS IN VIVO
ANIMAL EVALUATIONS
A comprehensive overview of the many in vitro and in vivo evaluation
methods available and their pros and cons with respect to demonstrat-
ing antimicrobial efficacies of biomaterials and coatings in clinical ap-
plications is beyond the scope of this paper. Nevertheless, it is important
to point out the long-standing challenge to establish reliable correlations
between in vitro results, in vivo data obtained in animal experiments,
and subsequent human in vivo performance. Table 2 summarizes fre-
quent flaws in design of both in vitro and in vivo animal (preclinical)
experiments that we consider central to this lack of correlation with
human outcome.
Apart from the flaws listed in Table 2, most in vivo experiments
are confined to small animals, like rats, mice, and rabbits, that may
have different immune responses than each other as well as humans.
Therefore, the bacterial challenges have to be carefully adjusted for the
animal selected to prevent acute death due to infection. Infection doses
for rabbits, for example, are usually much lower than for rats. Sub-
cutaneous evaluations of the combined presence of a biomaterial with
infecting bacteria are generally preferred, because in small animals, it
is difficult to shape the biomaterial and surgically implant it at the ap-
plication site aimed for.
Despite the drawbacks of current animal models, there are in-
teresting new developments that may improve translation of resultswww.ScienceTrto the clinic and allow more rapid screening of biomaterials for their
infection resistance and biocompatibility. To screen large numbers of
novel biomaterials for immune responses and infection, a zebrafish
embryo model is being developed (72). Zebrafish embryos have an in-
nate immune system with high similarity to that of humans and are
translucent (immune processes can be visualized in real time), and
their transcriptomes can be easily analyzed (72). Biomaterials may
then be selected for their capacity to induce specific desired expres-
sion of marker genes. In combination with fluorescently labeled
biomaterials and bacterial pathogens, this model holds promise for
speeding up development of infection-resistant biomaterials and
coatings.
Regardless of any experimental design and animal choice, however,
the best that in vitro and in vivo animal studies can provide is the
following:
(i) How much microbial adhesion and biofilm formation is in-
hibited or delayed on one biomaterial (coating) relative to another;
(ii) How many more organisms are killed on one biomaterial
(coating) versus another;
(iii) How tissue cells interact on different biomaterials (coatings);
or, more specifically,
(iv) How the race for the surface between microbial colonization
and tissue integration is influenced by surface design.
Although such information clearly is relevant to new biomaterial
and coating designs, the assays provide relative assessments in simpli-
fied formats. These assays cannot answer the most important question
often asked by funding and regulatory review panels, marketingTable 2. Common flaws in the design of in vitro and in vivo experiments in
animals aimed at demonstrating antimicrobial efficacy of an implant or de-
vice surface.
Evaluation should be in line with implant or device functionality
• Retains host immune system competence in clearance
• Facilitates host tissue integration
• Blocks microbial adhesion and growth
• Kills all organisms on and around the implant
• Evaluation for relevant duration of infection protection
Evaluation should be clearly aimed at primary or secondary implants or
devices after biomaterial-associated infection
• Surgical competence and experience
• Hospital hygiene conditions and re-enforcement through appropriate
protocols
• Presence of unaffected versus bacterially compromised tissue
• Duration of infection protection required
Evaluation method should be tailored to the physiological condition
at the implant site (permanent, totally internal, temporary, and/or
skin-penetrating)
• Ubiquitous presence of host protein conditioning films
• Use of relevant pathogenic species, causative to site-specific
biomaterial-associated infection
• Use of relevant bacterial challenge dosesanslationalMedicine.org 26 September 2012 Vol 4 Issue 153 153rv10 6
REV I EWdepartments in industry, and physicians: By what percentage is this
coating capable of reducing the incidence of biomaterial-associated in-








Most of the hundreds of antimicrobial coating approaches reported in
the literature fail in testing (73) or will not even reach the status of in vivo,
animal experiments. Many in vitro evaluations of new antimicrobial
coatings in the literature are rarely pursued by follow-up papers, pre-
sumably owing to negative results of further research or because fi-
nances for further research and necessary patents, including industrial
interest, are lacking. Approaches that have been taken to clinical ap-
plication very often encounter mixed enthusiasm, and it seems that no
antimicrobial biomaterial or coating has been embraced in the clinic
with the same enthusiasm as antibiotics when they were first discovered.
An exception to this is the class of antibiotic-releasing biomaterials and
coatings that have moved to clinical application (Table 3). Moreover,
true validation of infection-resistant biomaterials and coatings re-
quired for effective downstream translation can only be obtained inwww.ScienceTrhuman clinical trials, and unfortunately, this is often where develop-
ment of an antimicrobial biomaterial or coating terminates.
Let’s consider a hypothetical case: A design for an antimicrobial
coating on total hip prostheses that prevents infection associated with
perioperative microbial contamination has converged to a promising
prototype coating through extensive in vitro and in vivo animal test-
ing. Assuming an infection rate for total hip arthroplasties of 2%, a
simple power calculation shows that studies aiming to demonstrate
a 50% reduction in infection incidence, at a conservative statistical sig-
nificance of P < 0.05, requires the inclusion of around 5000 patients
that must be followed longitudinally over several years (and at a cost
of tens of millions of dollars). To demonstrate a 25% reduction (P < 0.05),
more than 22,000 patients have to be included (95). Clearly, these clinical
trials are too large, costly, and lengthy to be realistic and encourage
innovation, and hence, many such trials are never conducted. The re-
sult is that new technologies are not clinically validated or introduced.
We might consider a new reality in which the safety and efficacy of
biomaterials that prevent implant infection will not be substantiated
with clinical trials but instead will have to be derived from properly
designed in vitro and in vivo animal experiments that include bench-
marked, clinically widely accepted biomaterials for reference; this is
similar to the process taken by many orphan drugs, where insuffi-





rgTable 3. Exemplary materials and coatings undergoing clinical translation. The table only comprises a fraction of the hundreds of antimicrobial ideas and
concepts reported in the literature but which either fail early in translation or cannot be translated for the reasons described in this article.nc
emFunctionality Chemical basis Current statusanslationalMediciExamples of clinical applicationne.org 26 September 2012 Vol 4 Issue 153 1References.s
ci
eNonadhesive Hydrophilic polymer coatings Clinically appliedmContact lenses, hydrocephalic shunts,
endotracheal tubes, urinary catheters(74–76)st Polymer brush coatingsomIn vitro and in vivo
animal experimentsUnspecified (77) frTissue-integratingad
edArginine–glycine–aspartic acid
(RGD) peptide as a cell
adhesion promoterIn vitro Vascular graft (78)nl
oHydroxyapatite coatings Clinically applied Dental and orthopedic implants (79)owTitania thin-film coating In vitro Dental implants (80)DContact-killing Immobilized quaternary
ammonium compoundsIn vitro As yet unspecified (48)Selenium coatings In vitro Contact lenses (81)Silver coatings Clinically applied Urinary catheters (82)Antimicrobial-releasing Antibiotic-releasing acrylates Clinically applied Orthopedic joint prostheses (31, 32)Silver carbonate–, chlorhexidine
diacetate–releasingClinically applied Surgical meshes (83, 84)Antibiotic-releasing Clinically applied Endovascular stent (85–87)Silver, chlorhexidine, rifampicin,
or minocycline coatingsClinically applied Vascular catheters (88, 89)Triclosan-releasing sutures Clinically applied Sutures (90, 91)Gentamicin/biodegradable
polymer coatingClinically applied Tibia nail, surgical meshes (3, 92)Multifunctional coating Polymer brush/antibiotic
co-graftedChemical drawing
board, in vitroUnspecified, possibly for titanium
implants(56, 93, 94)Polymer brush/cell-ligand
co-graftedChemical drawing board,













rguse. Animal trials with relatively high bacterial challenge doses may
show antimicrobial efficacy for biomaterial surfaces or coatings, but to
demonstrate an actual reduction of infection incidences with lower,
clinically relevant challenge doses, more comparable to the clinical sit-
uation with patients, the numbers of animals required would be as high
as the numbers of patients, making the costs of such animal studies
prohibitive as well. This poses a dilemma not only to biomaterial im-
plant and device companies but also to funding and regulatory agen-
cies, because it implies that the true clinical impact and economic
value generation of new, anti-infection biomaterial designs cannot
be accurately estimated.
The implant infection issue is too important to patients, however,
to be deadlocked in this maze of uncertainties and impossibilities.
Therefore, to facilitate translation of new coating approaches to clin-
ical application, so-called combination devices—implants or devices
supplemented with secondary on-board drug therapies—are offered
a unique regulatory review process (3). In combination devices, clini-
cally approved components are combined into a single platform, such
as the gentamicin-releasing orthopedic tibia nail or paclitaxel-eluting
coronary stent. Despite good intentions of regulatory bodies, such as the
U.S. Food and Drug Administration, combination devices still undergo
lengthy approval processes that include clinical trials to substantiate
claims for antimicrobial efficacy of biomaterials and coatings for im-
plants and devices. Academic institutions, industries, and funding and
regulatory agencies will all have to find better ways to rely on indirect in

















Given the competition between tissue integration and bacterial colo-
nization inherent in the race for the surface, a frequently asked ques-
tion is whether new tissue-engineered constructs or devices will provide
new opportunities to win the race. Tissue engineering may be the ul-
timate solution to restore function when the human body is compro-
mised beyond natural repair. Tissue-engineered scaffold materials are
implanted directly, or after being seeded and cultured with cells (96, 97),
ECM proteins, and growth factors most appropriate to the in vivo ap-
plication site. However, such constructs and devices must also be sur-
gically implanted to regenerate the desired tissue form and functionality
and to integrate with host tissues. As biomaterial-based scaffolds, both
acellular and cellularized implants are at equal risk of peri- and early
postoperative microbial contamination.
Furthermore, host immune response may not develop sufficiently
around implantation sites to clear microbial contamination. In a unique
evaluation of 228 implanted polymeric, porous scaffolds in rabbit knee
osteochondral defects, 6 scaffolds without cells (3.6%) and 4 identical
scaffolds seeded with cartilage cells (6.3%) appeared to demonstrate
clinical signs of infection within 3 to 9 weeks (98). These infection in-
cidences are comparable with those currently seen for acellular bio-
material implants and devices in patients (Table 1). Apparently, even
preseeded cells on a biomaterial cannot outcompete bacteria in their
attempt to colonize a scaffold surface, indicating that infection control
measures should be part of the development process of any tissue-
engineered constructs and devices. Here, too, the concept of tissue in-
tegration over microbial colonization, as proposed by Gristina (10),
provides an important guideline for which coculture assays may be
indispensable tools.www.ScienceTrA FINISH LINE IN THE RACE FOR THE SURFACE
The challenges in producing new infection-resistant, antimicrobial
biomaterials and coatings for implants and devices have stubbornly
persisted for many years. This Review identifies difficult barriers in
understanding the backgrounds of this problem and therewith pro-
vides direction to accelerate progress as demanded by society, by out-
lining flaws in current research and development processes that impede
downstream translation of new ideas to human use. Moreover, this
Review enforces a proposed shift to multifunctional surface coatings,
which are expected to perform better than current generations of mono-
functional coatings. We also highlight an experimental need to simul-
taneously evaluate tissue integration, bacterial colonization, and immune
responses before biomaterials can be tested in clinical trials.
Clinical trials, however, are cumbersome because the number of
patients acquiring a biomaterial-associated infection is low and such
trials necessitate inclusion of thousands of patients, which are often
too large, costly, and lengthy to be pursued. Because downstream
translation into clinical practice is the ultimate goal, these considera-
tions yield the unavoidable, simple conclusion that claims for medical
implant and device infection prevention should be accepted without
clinical trials on the basis of in vitro and in vivo studies. Such studies
are expected to extrapolate clinical efficacy as long as clinically bioma-
terials are used for reference, and the primary implant or device func-
tion is not adversely affected by adding antimicrobial coatings. To ensure
patient safety, we need to scrutinize post-marketing surveillance re-
sults for unanticipated adverse effects.
Production of infection-resistant antimicrobial biomaterials and
coatings will not only benefit the current generation of patients relying
on biomaterial implants or devices. Past prototypes of the artificial
heart, for instance, have bluntly ignored the risks of infection. Surpris-
ingly, the upcoming field of tissue engineering largely also continues to
neglect the risks of infection. With an eye on the future, prototypes of
tissue-engineered constructs and devices are needed that include infection-
resistant antimicrobial biomaterials and coatings. Otherwise, smooth
translation to clinical applications will be cumbersome, positioning the
finish line in the race for the surface farther away than needed.REFERENCES AND NOTES
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